Medium materiality5/10
Cantor Fitzgerald raises AbbVie price target to $325
Why it may matterVerify against the original reporting
Bullish analyst update, tempered by the fact that the target is an opinion rather than a company development.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Cantor Fitzgerald raised its ABBV price target to $325 from an unspecified prior target. The new target is about 13% above the posted price of $287.17.
- Cantor Fitzgerald raised its ABBV price target to $325.
- The new target implies roughly 13% upside from the posted price.
Key facts
- 01
Target: $325
- 02
Posted price: $287.17
- 03
Analyst firm: Cantor Fitzgerald
- 04
Analyst: Carter Gould
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.